SCHEMBL4710744

SCHEMBL4710744

FC(F)(F)c1cccc(C(F)(F)F)c1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.40
CYP19A1 P11511 3/20 0.39
TSHR P16473 2/20 0.38
MAPK1 P28482 2/20 0.38
HIF1A Q16665 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
PPARG P37231 4/20 0.37
CNR2 P34972 1/20 0.36
PPARA Q07869 1/20 0.35
CNR1 P21554 3/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083407 0.83 P2RX7 (0.45) P2RX7TDP1LMNAHPGDALDH1A1
SCHEMBL6262863 0.70 CNR2 (0.47) P2RX7TSHRMAPK1HIF1ATDP1
SCHEMBL4189236 0.69 CNR2 (0.49) P2RX7TSHRMAPK1HIF1ATDP1
SCHEMBL4088048 0.68 CYP19A1 (0.70) CYP19A1TSHRMAPK1HIF1ATDP1
SCHEMBL11227967 0.68 P2RX7 (0.42) P2RX7CYP1A2
SCHEMBL807279 0.68 P2RX7 (0.48) P2RX7TSHRHIF1ATDP1LMNA
SCHEMBL18419809 0.67 P2RX7 (0.41) P2RX7
SCHEMBL12985854 0.67 P2RX7 (0.49) P2RX7LMNAALDH1A1CYP1A2
SCHEMBL1043059 0.67 P2RX7 (0.57) P2RX7TDP1ALDH1A1POLB
Hydrochloric Acid SCHEMBL7782034 0.66 CYP19A1 (0.67) CYP19A1TSHRMAPK1HIF1ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962834-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Aventis Pharmaceuticals Inc. (US) 2008-09-03 EP disclosed
WO-2007067617-A2 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA AVENTIS PHARMACEUTICALS INC. (US) 2007-06-14 WO disclosed